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Colorectal cancer (CRC) is the third most leading cause of morbidity and mortality throughout the world. 5-
fluorouracil (5-FU), which is often administrated to disrupt carcinogenesis, was found to elevate blood glucose 
level among CRC patients. Thus, this study was conducted to evaluate the influence of rosiglitazone on antipro-
liferative effect of 5-FU using cellular model. Two human colonic carcinoma cell lines (HCT 116 and HT 29) 
were cultured in the presence of 5-FU, rosiglitazone or in combination under normal and high glucose concentra-
tion. The drug cytotoxicity was evaluated using the MTT assay whereas the assessment of cell cycle was carried 
out using the flow cytometry technique. Combination index (CI) method was used to determine the drug interac-
tion between rosiglitazone and 5-FU. High glucose diminished the cytotoxic effect of 5-FU but at a high drug 
dosage, this effect could be overcome. Cell cycle analysis demonstrated that 5-FU and rosiglitazone caused G1-
phase arrest and S-phase arrest, respectively. CI values indicated that rosiglitazone exerted synergistic effect on 
5-FU regardless of glucose levels. This study is the first to demonstrate the influence of rosiglitazone on cytotox-
icity of 5-FU under normal or high glucose level. Rosiglitazone may be a promising drug for enhancing the effi-
cacy of 5-FU in the treatment of CRC associated with hyperglycemia. 
 





Colorectal cancer (CRC) is the third most 
leading cause of morbidity and mortality 
throughout the world (Ferlay et al., 2015). It 
is estimated that over one million new cases 
are diagnosed per year, which accounts for 
around 10 % of all cancer incidences in both 
sexes. 
Chemotherapy with curative intent is of-
ten applied as a first-line treatment to disrupt 
carcinogenesis. In this context, 5-fluorouracil 
(5-FU) plus leucovorin is the main option for 
CRC patients (Goodwin and Asmis, 2009). 
Other active agents such as irinotecan, cape-
citabine, oxaliplatin, bevacizumab, cetuxi-
mab or panitumumab are also adopted in 
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fluorouracil-based therapy to improve over-
all survival and reduce the risk of disease 
recurrence. Unfortunately, the clinical effi-
cacy is highly dose-dependent due to phar-
macokinetic variability and it causes severe 
toxicities in some CRC patients despite the 
administration of standard drug protocol 
(André et al., 2004). 
Based on previous epidemiological stud-
ies, diabetes mellitus is suggested to be an 
independent risk factor for colorectal cancer. 
Although the relationship is not entirely un-
derstood, most findings concur with a posi-
tive association between diabetes and colo-
rectal cancer (de Bruijn et al., 2013; Deng et 
al., 2012; Krämer et al., 2012; Larsson et al., 
2005; Luo et al., 2012; Mills et al., 2013). 
Giovannucci et al. (2010) reported that plau-
sible biological mechanisms underlying this 
association can be attributed to the effect of 
hyperglycemia, hyperinsulinemia or inflam-
mation on cancer aetiology and progression. 
An improved glucose control should be an 
important therapeutic approach for CRC pa-
tients.  
Besides metformin, thiazolidinediones 
including rosiglitazone and pioglitazone are 
another class of oral antidiabetic drugs which 
help to protect against hyperglycemia (Yki-
Järvinen, 2004). Thiazolidinediones increase 
insulin sensitivity by activating one or more 
peroxisome proliferator-activated receptors 
(PPARs) to regulate glucose utilization and 
production. Several in vitro studies indicated 
that rosiglitazone acts as a PPAR-gamma 
agonist which suppresses cell proliferation, 
inhibits cell invasiveness, arrests cell cycle 
and induces apoptosis in cancer cell lines 
(Cao et al., 2009, 2015; Han and Roman, 
2006; He et al., 2008; Lin et al., 2007; Zhang 
et al., 2008a). These anticancer properties 
provoke the use of rosiglitazone on individu-
als who developed diabetic complications 
during or after fluorouracil-based regimen.  
A recent meta-analysis showed a de-
creased risk of colorectal cancer incidence 
when rosiglitazone was administered to dia-
betic patients (Monami et al., 2014). While 
high glucose can modulate cytotoxicity of 5-
FU (Ma et al., 2014), the efficacy of rosig-
litazone is possibly affected by the level of 
hyperglycemic condition. In this study, the 
influence of rosiglitazone on 5-FU pretreated 
human colon cancer cell lines was evaluated 
at high glucose level. The drug interaction 
between rosiglitazone and 5-FU was also 
determined. 
 
MATERIAL AND METHODS 
Reagents 
Blank glucose Dulbecco's Modified Ea-
gle Medium (DMEM) (Cat. no.: 11966) and 
normal glucose DMEM (Cat. no: 11885) 
were purchased from ThermoFisher. High 
glucose DMEM (D5671 Sigma) was com-
plemented with 4.0 mM L-glutamine, 1.0 
mM sodium pyruvate, 10 % fetal bovine 
serum, 1 % penicillin streptomycin and 1 % 
amphoterin B. The stock solutions of 5-FU 
(F6627 Sigma) and rosiglitazone (R2408 
Sigma) were prepared in phosphate-buffered 
saline (PBS) and dimethyl sulfoxide 
(DMSO) with a concentration of 5 mg/ml 
and 1 mg/ml respectively. MTT formazan 
powder (M5655 Sigma) was dissolved in 
PBS and diluted to 5 mg/ml. Propidium io-
dide (PI, Cat. no: P1304MP) and RNAse A 




Two human colonic carcinoma cell lines, 
namely HCT 116 and HT 29, were cultured 
in normal glucose DMEM (Cat No: 11885) 
supplemented with 10 % fetal bovine serum, 
1 % penicillin streptomycin and 1% am-
photerin B. A human normal colon cell line 
(CCD-18Co) was cultured in normal glucose 
Minimum Essential Medium Eagle (MEME, 
D2279 Sigma) complemented with 4.0 mM 
L-glutamine, 1.0 mM sodium pyruvate, 20 % 
fetal bovine serum, 1 % non-essential amino 
acid and 1 % penicillin streptomycin. All cell 
lines were maintained in humidified atmos-
phere of 5 % CO2 at 37±2 °C. 
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Cell proliferation assay 
HCT 116 cells, HT 29 cells and CCD-
18Co cells were seeded into 96-well plates at 
a density of 2000 cells/100 µl, 2500 
cells/100 µl and 3500 cells/100 µl per well 
respectively. After incubation at 37±2 °C for 
24 h, the cells were then treated with 5-FU or 
rosiglitazone at various concentrations for 
48 h. Next, 10 µl of MTT was added and the 
plates were incubated in the dark at 37±2 °C 
for 3 h. After solubilizing the formazan crys-
tals in 100 µl DMSO, absorbance was meas-
ured at 560 nm. The cell proliferation was 
calculated as follows: {[absorbance of treat-
ed group-absorbance of blank] ⁄ [absorbance 
of control group-absorbance of blank]} × 
100. The IC20 and IC50 were determined 
through linear regression analysis. 
 
Cell cycle assay 
For the cell cycle assay, drug treatment 
was carried out in 12-well culture plates with 
a density of 40, 000 cells/ml/well (HCT 116) 
and 55, 000 cells/ml/well (HT 29) at 37±2°C 
for 48 h. The cells were harvested and fixed 
in 2 ml of cold 70 % (v/v) absolute ethanol 
and stored overnight at -20 °C. Then, the 
fixed cells were washed twice with PBS. 
Cell staining was done by sequentially add-
ing 450 µl PBS, 25 µl RNAse A (1 mg/ml) 
and 50 µl PI (0.1 mg/ml). The stained cells 
were incubated in the dark at room tempera-
ture (25±2 °C) for 30 min and further exam-
ined by a flow cytometer (BD FACScanto II) 
integrated with BD FACSDiva Software. 




First, the cell proliferation of HCT 116 
and HT 29 under normal glucose (NG, 
5.5mM) and high glucose (HG, 25mM) cul-
ture conditions for 48 h was carried out. The 
complete blank glucose DMEM containing 
1.0 mM sodium pyruvate, 10 % fetal bovine 
serum, 1 % penicillin streptomycin and 1 % 
amphoterin B served as a negative control 
whereas NG DMEM+19.5 mM D-mannitol 
and blank glucose DMEM+25 mM D-
mannitol were the osmotic controls. The cell 
proliferation of CCD-18Co cells was evalu-
ated at different glucose concentrations with 
NG MEME+19.5 mM D-mannitol as an os-
motic control. 
To study the effect of glucose on drug 
cytotoxicity, both cancer and normal cells 
lines were pre-treated with 0.2 µg/ml 5-FU 
for 24 h. Then, spent culture media was aspi-
rated and replaced with the following exper-
imental media: (i)NG medium+0.2 µg/ml 5-
FU; (ii)NG medium+2 µg/ml 5-FU; (iii)HG 
medium+0.2 µg/ml 5FU; (iv)HG medium+2 
µg/ml 5-FU. The control group was 5-FU 
pre-treated cells in NG medium without any 
drug treatment for subsequent 48 h incuba-
tion. The same experiment was repeated with 
treatments of rosiglitazone alone and a com-
bination of 5-FU and rosiglitazone. In this 
study, low dose was defined as a concentra-




SPSS Statistics 17.0 software, ANOVA 
followed by Duncan Multiple Range Test 
was performed to analyse the data. Value of 
p< 0.05 was considered statistically signifi-
cant. All results were expressed as 
mean±SEM from three independent experi-
ments of at least three replicates.  
 
RESULTS 
Effect of 5-FU and rosiglitazone on cell 
proliferation 
Figure 1 shows the cell proliferation of 
HCT 116 and HT 29 cells upon treatment 
with increasing concentrations of 5-FU or 
rosiglitazone. Both cell lines showed a dose-
dependent decrease in cell proliferation. 
HCT 116 responded to 5-FU (Figure 1A1) at 
IC50= 4.77±0.55 µg/ml and rosiglitazone 
(Figure 1B1) at IC50= 11.61±3.49 µg/ml. The 
respective drugs resulted in lower IC50 values 
of 1.86±0.18 µg/ml (5-FU, Figure 1A2) and 
1.04±0.14 µg/ml (rosiglitazone, Figure 1B2) 
on HT 29. Since the IC20 of both drugs was 
comparable between HCT 116 and HT 29, a 
low dose of 5-FU at 0.2 µg/ml and rosiglita-
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zone at 0.5 µg/ml were selected. 5-FU and 
rosiglitazone did not exert any significant 
effect at the low dose range but showed 30-
40 % inhibition at extremely high concentra-
tion (>10 µg/ml) on CCD-18Co cells (Fig-
ures 1A3 and 1B3). 
Figure 1: Effect of drug treatment on the cell proliferations. Cells were treated with (A) 5-FU or (B) 
rosiglitazone at various concentrations for 48 h. The control group were untreated cells in normal glu-
cose medium. *Compared to control, p <0.05. 
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In HG culture, the cell proliferation was 
stimulated significantly 0.7 fold (HCT116, 
Figure 2A1) and 1.6 fold (HT29, Figure 2A2) 
compared with NG culture. Subsequent in-
troduction of high glucose (25 mM) even 
reduced the inhibitory effect of 5-FU. 
Figure 2: Effect of glucose on drug treatments. (A) HCT 116 and HT29 cells were treated in NG or 
HG culture for 48 h. The control group were cells incubated in blank medium. Two media containing 
mannitol with a concentration of iso-osmolar to HG was used as osmotic controls. CCD-18Co cells 
were cultured at different glucose concentrations. (B-C) 5-FU pretreated cells with subsequent low 
dose or high dose of drug treatments in blank (absent on CCD-18Co), NG and HG media for 48 h. The 
control group were 5-FU pre-treated cells in NG culture without any subsequent drug treatments.  
*Compared to control, p <0.05. **Compared to NG group, p <0.05. NG, normal glucose (5.5 mM); HG, 
high glucose (25 mM) Panel B: 5-FU, low dose =0.2 µg/ml; high dose =2 µg/ml, Panel C: Rosiglita-
zone, low dose =0.5 µg/ml; high dose =5 µg/ml 
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At low dose of 5-FU (0.2 µg/ml), HG 
culture significantly (p< 0.05) increased the 
cell proliferation of HCT 116 up to 124 % 
(Figure 2B1). The cell proliferation of HT 29 
was approximately 105 % in HG culture and 
it was significantly (p< 0.05) higher than that 
in NG culture (80 %) (Figure 2B2). At low 
dose of rosiglitazone (0.5 µg/ml), a signifi-
cant difference (p< 0.05) in cell prolifera-
tions between HG culture (HCT 116= 100%; 
HT 29= 99 %) and NG culture (HCT 116= 
80 %; HT 29= 85 %) was evident (Figures 
2C1 and 2C2). The viability of both cell lines 
was less than 30 %, either in HG or NG cul-
ture, when treated with a high dose of rosig-
litazone (5 µg/ml). Glucose level had no sig-
nificant effect on CCD-18Co cells regardless 
of drug treatment (Figures 2B3 and 2C3). 
Figures 3A and 3B show the cell prolif-
erations of HCT 116 and HT 29 respectively 
when 5-FU and rosiglitazone were used in 
combination. At low dose of 5-FU, an addi-
tion of low dose rosiglitazone significantly 
(p< 0.05) decreased the cell proliferation of 
HCT 116 from 118 % to 96 % in HG culture 
while the same treatment had no effect on 
HT 29. At high dose of 5-FU, an addition of 
low dose rosiglitazone in HG culture trig-
gered the cells to proliferate at an equivalent 
rate to those treated with single dose of 5-
FU. The two cell lines maintained viability 
below 20 % with combined drugs containing 
high dose of rosiglitazone in NG and HG 
cultures. Similarly, glucose level had no sig-
nificant effect on CCD-18Co cells regardless 
of drug treatment (Figure 3C). 
 
Effect of 5-FU and rosiglitazone on cell  
cycle 
Exposure to low dose 5-FU caused G1 
phase arrest on HCT 116 cells cultured in 
NG (82.02±1.35 %) and HG (62.83±0.99 %) 
conditions (Figure 4). However, low dose 
rosiglitazone arrested the cells in S phase in 
HG culture (52.25±1.70 %). In the presence 
of both 5-FU and rosiglitazone, G1 phase 
arrest was observed in NG (78.06±0.74 %) 
with S-phase cells significantly (p< 0.05) 
increased from 12.27±1.57 % to 
21.26±0.73 % and HG (61.01±1.17 %) cul-
tures. Under the similar treatments, HG cul-
ture significantly increased the cell propor-
tion in S phase when compared to those in 
NG culture. 
In NG culture, HT 29 cells treated with 
low dose 5-FU were arrested in S phase 
(50.62±0.94 %) as shown in Figure 5. Low 
dose of rosiglitazone induced G1 phase ar-
rest but significantly (p< 0.05) increased the 
proportion of S phase-cells from 
30.37±1.66 % to 37.97±1.84 %. Treatment 
with 5-FU or rosiglitazone had no effect on 
the cell cycle in HG culture. The significant 
(p< 0.05) increase in cell proportion, 
43.16±1.52 % (NG) and 30.32±2.46 % (HG), 
was observed in S phase when treated with 
both drugs together. Regardless of drug 
treatment, HG culture significantly (p< 0.05) 
increased the cell proportion in G2 phase 
when compared with NG culture. 
 
DISCUSSION 
Warburg hypothesis postulates that the 
origin of carcinogenesis is a change of me-
tabolism which is often associated with en-
hanced glucose uptake and consumption in 
cancer cells (vander Heiden et al., 2009). In 
this respect, hyperglycemia can be a primary 
glucose source to meet the metabolic de-
mand of fast growing cancerous cells. Sever-
al in vitro studies have demonstrated that 
high glucose levels promote the proliferation 
of human colorectal carcinomas (Ma et al., 
2014; Masur et al., 2011; Tomas et al., 2012) 
which concur with the result obtained in this 
study. The increase in cell proliferation 
could be independent of osmotic stress as it 
was reproduced by D-mannitol with a signif-
icant difference against normal glucose. It 
was differed to normal cells which had no 
respond to glucose level (Figure 2A3). 
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Figure 3: Effect of combined drugs on cell proliferation under NG or HG culture. 5-FU pretreated cells 
were further exposed to 5-FU alone or in combination with rosiglitazone for 48 h incubation. The con-
trol group were 5-FU pre-treated cells in NG culture without any subsequent drug treatments. 
*Compared to control, p <0.05. **Compared to single dose 5-FU, p <0.05. 
NG, normal glucose (5.5 mM); HG, high glucose (25 mM) 
a0.2 µg/ml as low dose 5-FU; 2 µg/ml as high dose 5-FU 
LRz, low dose rosiglitazone= 0.5 µg/ml 
HRz, high dose rosiglitazone= 5 µg/ml  
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Figure 4: 5-FU pretreated cells (HCT 116) were exposed to different drug treatments for 48 h incuba-
tion in the present of normal glucose (NG) or high glucose (HG). (A) Data are presented as 
mean±SEM from three independent experiments in at least three replicates. Numbers in bold are sig-
nificantly different compared to the values of untreated cells, p <0.05. (B) Representative DNA content 
histograms analyzed by Modfit software.  
*Compared to NG group with the same treatment, p <0.05. 
NG, normal glucose (5.5 mM); HG, high glucose (25 mM) 
Concentration of 5-FU= 0.2 µg/ml; Concentration of rosiglitazone= 0.5 µg/ml 
G1: Interphase Gap1; S: Interphase Synthesis; G2: Interphase Gap2 
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Figure 5: 5-FU pretreated cells (HT 29) were exposed to different drug treatments for 48 h incubation 
in the present of normal glucose (NG) or high glucose (HG). (A) Data are presented as mean±SEM 
from three independent experiments in at least three replicates. Numbers in bold are significantly dif-
ferent compared to the values of untreated cells, p <0.05. (B) Representative DNA content histograms 
analyzed by Modfit software.  
*Compared to NG group with the same treatment, p <0.05. 
NG, normal glucose (5.5 mM); HG, high glucose (25 mM) 
Concentration of 5-FU= 0.2 µg/ml; Concentration of rosiglitazone= 0.5 µg/ml 
G1: Interphase Gap1; S: Interphase Synthesis; G2: Interphase Gap2 
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5-FU is widely used to treat metastatic 
colorectal cancer. It is a uracil analog and 
principally works through irreversible inhibi-
tion of thymidylate synthase (TS), an en-
zyme responsible for the conversion of de-
oxyuridylate (dUMP) to deoxythymidylate 
(dTMP) under normal physiological condi-
tions (Zhang et al., 2008b). 5-FU is convert-
ed to fluorodeoxyuridine monophosphate 
(FdUMP) which competes with dUMP in 
binding to TS and thus limiting dTMP pro-
duction. The dTMP depletion can lead to 
cytotoxicity causing cell death via thy-
mineless death (Longley et al., 2003). Alt-
hough cytotoxicity of 5-FU in colorectal cell 
lines have been extensively determined 
(Failli et al., 2011, 2013; Flis and 
Spławiński, 2009; Wiebke et al., 2003), the 
role of glucose concentrations in altering the 
drug cytotoxicity still need to be clarified. In 
the present study, we showed that 5-FU and 
high glucose affected the cancer cell prolif-
eration antagonistically. 
As demonstrated in the study, the cyto-
toxicity of 5-FU in colorectal cancer cells 
was diminished by HG treatment, a concen-
tration equivalent to the serum glucose level 
in diabetic individuals (glucose level 
>200 mg/dl). Conversely, proliferative effect 
of high glucose could be overcome when 
dosage of the drug was high enough. Ma et 
al. (2014) speculated that a higher admin-
istration dosage is required to sustain the 
therapeutic effect of 5-FU for CRC patients 
with hyperglycemia. Unfortunately, cases of 
5-FU toxicity have been reported on diabetic 
patients and the severity was directly related 
to the degree of hyperglycemia (Sadoff, 
1998). It implicated that administration of 5-
FU can pose a threat to developing drug tox-
icity if blood glucose was poorly managed. 
Past clinical investigations have proposed 
that deficiency of, either dihydropyrimidine 
dehydrogenese or dihydropyrimidinase, is a 
pharmacogenetic disorder associated with 5-
FU toxicity (Milano et al., 1999; van Kui-
lenburg, 2004; van Kuilenburg et al., 2003), 
but the activities of these 5-FU catabolic 
enzymes in the cancer patients with diabetes 
are still not fully understood. 
As the mainstay of chemotherapy for 
colorectal cancer, some common adverse 
events induced by 5-FU have been reported, 
namely mucositis, diarrhea and myelosup-
pression (Vincenzi et al., 2008). 5-FU was 
also found to elevate blood glucose level in 
CRC patients (Köhne et al., 1997; Tayek and 
Chlebowski, 1992). A recent study even 
concluded that hyperglycemia is a potent 
complication due to 5FU-based regimen 
(Feng et al., 2013). To address this issue, 
groups of antidiabetic agents including insu-
lin analogs, insulin sensitizers, secretagogues 
and incretin mimitics are currently being 
considered. Based on a review by García-
Jiménez et al. (2016), agents that improve 
insulin sensitivity may reduce cancer risk 
rather than those that increase circulating 
insulin. Therefore, rosiglitazone as an insulin 
sensitizer should be appropriately applied in 
combination with 5-FU when taking cancer 
risk factors into consideration. 
Ample evidences showed that rosiglita-
zone, a PPAR-gamma agonist suppressed 
proliferation of various cancerous cells at 
concentrations varying from 0.1 µmol/L to 
100 µmol/L (Cao et al., 2009, 2015; Han and 
Roman, 2006; He et al., 2008; Lin et al., 
2007; Zhang et al., 2008a). Similarly, in the 
present study, 5-FU pretreatment followed 
by a comparable dosage of rosiglitazone in-
hibited cell growth of HCT 116 and HT 29. 
While only one glucose concentration 
(16.67 mM or 11.11 mM) was used in the 
previous related studies (Lin et al., 2007; 
Miao et al., 2011; Zhang et al., 2007), this 
study demonstrated that the inhibitory effect 
of rosiglitazone was modulated by glucose 
levels. Activation of PPAR-gamma by rosig-
litazone stimulates the expression of phos-
phate and tension homolog (PTEN) in hu-
man carcinoma cell lines (Han and Roman, 
2006; Cao et al., 2009). When glucose level 
is high, the PTEN expression is decreased 
leading to an increased Akt activity (Liu et 
al., 2012; Mahimainathan et al., 2006). The 
deregulation of Akt signaling allows cell 
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survival and cell growth which may explain 
why the inhibitory effect of rosiglitazone 
was significantly (p< 0.05) reduced in HG 
culture (Figures 2C1-C2). There are other 
possible downstream regulations via a 
PPAR-gamma dependent signal pathway 
such as COX-2, MMP-7 and TIMP-1 (Miao 
et al., 2011).  
5-FU treatment causes DNA damage due 
to misincorparation of FdUTP into DNA 
(Longley et al., 2003). While cell cycle pro-
gression is regulated by checkpoint control 
in the G1 or G2 phase, cycle arrests in G1 
and G2 phases allow DNA repair prior to 
replication and mitosis respectively. In the 
present study, low dose of 5-FU appeared to 
trigger cytostasis via G1 phase arrest on 
HCT 116 cells but S phase arrest on HT 29 
cells in NG culture. The different cell cycle 
response might be due to the variance in mu-
tation status of HCT 116 (MMR-
deficient/p53-proficient) and HT 29 (MMR-
proficient/p53-deficient). Admittedly, MMR-
deficient cell lines confer less sensitivity to 
5-FU (Adamsen et al., 2011) thus, HG could 
diminish G1 phase arrest on 5FU-treated 
HCT 116 cells. The result was consistent 
with the increase of cell proliferation at high 
glucose level (Figure 2B1). On the other 
hand, Hawn et al. (1995) suggested that any 
agent that induces DNA mispairs will lead to 
G2 arrest in MMR-proficient cells. The in-
crease of HT 29 cells in G2 phase corre-
sponded to the increase of cell proliferation 
(Figure 2B2) indicating that the mismatch 
repair (MMR) system interacted with G2 
checkpoint in response to 5-FU, especially at 
high glucose level for DNA repair which 
allow cell replication. Unlike 5-FU, low dose 
rosiglitazone induced S-phase arrest and this 
differed to the effects whereby G1-phase 
arrest was evident on gastric cancer (He et 
al., 2008), breast cancer (Zhang et al., 
2008a), and liver cancer (Yu et al., 2010). In 
fact, rosiglitazone was also reported to cause 
G1-phase arrest in colorectal cancers at 
higher concentrations specifically 10 µmol/L 
(HT 29) (Lin et al., 2007) and 25 µmol/L 
(HCT 15) (Miao et al., 2011). These conflict-
ing results suggested that low dose of rosig-
litazone might trigger the cells to experience 
genotoxic stress during DNA replication and 
delay their progression in a transient manner 
through activation of intra-S-phase check-
point (Bartek et al., 2004). Proteins that may 
be involved in the intra-S-phase checkpoint 
are kinase Chk1, MSH2 and MCH 1. It is 
possible to enhance the efficacy of 5-FU if 
DNA synthesis can be inhibited by regulat-
ing the TS levels during the S phase of cell 
cycle (Subbarayan et al., 2010). The down-
regulation of TS induces p53 protein expres-
sion (Liu et al., 2002) and initiates cell apop-
tosis consequently. 
To determine the drug interaction be-
tween rosiglitazone and 5-FU, the cytotoxici-
ty outcomes from individual and combined 
drug treatments were further analyzed using 
combination index (CI) method (Chou and 
Talalay, 1983, 1984). Based on CI values 
generated by CompuSyn software version 
1.0 (data not shown), the present study re-
vealed that high dose of rosiglitazone exerted 
synergistic effect on 5-FU treatment regard-
less of glucose levels. Indeed, it was far 
more effective than 5FU/metformin combi-
nation whereby the cell growth suppression 
occurred at a higher dosage of both drugs 
(Zhang et al., 2013). Addition of low dose 
rosiglitazone was antagonistic to 5-FU, 
meaning that the combined drugs had an 
overall effect that was less than the sum of 
their individual effect. The cell cycle analy-
sis reflected a similar trend between 5-FU 
treatment and combined drug treatment, 
whereby the highest cell proportion occurred 
in G1 phase followed by S phase and G2 
phase under NG or HG culture. 
 
CONCLUSION 
This study is the first attempt to demon-
strate the influence of rosiglitazone on cyto-
toxicity of 5-FU under normal or high glu-
cose condition. The present results showed 
that rosiglitazone had an antiproliferative 
effect on colorectal cancer cells via G1 or S 
phase arrest. Moreover, the antiproliferative 
effect was synergistic to 5-FU drug in the 
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presence of high glucose. Thus, combining 
rosiglitazone in 5-FU regimen may improve 
the therapeutic effect. Taken together, the 
present finding provides a better insight for 
the management of hyperglycemic CRC pa-
tients on 5-FU chemotherapy.  
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